Epothilones as Natural Compounds for Novel Anticancer Drugs Development

Primer Autor
Paz, Cristian
Co-autores
Villegas, Cecilia
Gonzalez-Chavarria, Ivan
Burgos, Viviana
Iturra-Beiza, Hector
Ulrich, Henning
Título
Epothilones as Natural Compounds for Novel Anticancer Drugs Development
Editorial
MDPI
Revista
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Lenguaje
en
Resumen
Epothilone is a natural 16-membered macrolide cytotoxic compound produced by the metabolism of the cellulose-degrading myxobacterium Sorangium cellulosum. This review summarizes results in the study of epothilones against cancer with preclinical results and clinical studies from 2010-2022. Epothilone have mechanisms of action similar to paclitaxel by inducing tubulin polymerization and apoptosis with low susceptibility to tumor resistance mechanisms. It is active against refractory tumors, being superior to paclitaxel in many respects. Since the discovery of epothilones, several derivatives have been synthesized, and most of them have failed in Phases II and III in clinical trials, however, ixabepilone and utidelone are currently used in clinical practice. There is robust evidence that triple-negative breast cancer (TNBC) treatment improves using ixabepilone plus capecitabine or utidelone in combination with capecitabine. In recent years innovative synthetic strategies resulted in the synthesis of new epothilone derivatives with improved activity against refractory tumors with better activities when compared to ixabepilone or taxol. These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs.
Fecha Publicación
2023
Tipo de Recurso
artículo de revisión
doi
10.3390/ijms24076063
Formato Recurso
PDF
Palabras Claves
epothilones
epothilone derivates
cytotoxicity
anticancer agents
refractory cancer
taxanes
clinical trials
Ubicación del archivo
http://dx.doi.org/10.3390/ijms24076063
Categoría OCDE
Bioquímica y biología molecular
Química
Materias
epotilonas
derivados de epotilona
citotoxicidad
agentes anticancerígenos
cáncer refractario
taxanos
ensayos clínicos
Identificador del recurso (Mandatado-único)
artículo de revisión
Versión del recurso (Recomendado-único)
versión publicada
License
CC BY 4.0
Condición de la licencia (Recomendado-repetible)
CC BY 4.0
Derechos de acceso
acceso abierto
Access Rights
acceso abierto
Id de Web of Science
WOS:000969832300001
ISSN
1661-6596
Tipo de ruta
verde# dorado
Categoría WOS
Bioquímica y biología molecular
Química
Referencia del Financiador (Mandatado si es aplicable-repetible)
FAPESP 2018/07366-4
FAPESP 201808426-0
ANID-FONDECYT 1220831
ANID FONDECYT 11181105
ANID FONDECYT 1220831
Colecciones
Colección Publicaciones Científicas
Colección ANID
Revisa las metricas alternativas de Almetrics
Revisa las citaciones de Dimensions